Loading...
XSTOQUIA
Market cap1mUSD
Dec 23, Last price  
0.01SEK
1D
-15.70%
1Q
-34.98%
Jan 2017
-100.00%
IPO
-100.00%
Name

QuiaPEG Pharmaceuticals Holding AB

Chart & Performance

D1W1MN
XSTO:QUIA chart
P/E
—
P/S
4.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
163.21%
Rev. gr., 5y
5.31%
Revenues
4m
-21.53%
9,170,00010,228,0009,680,00012,701,0009,695,00013,057,0009,268,00014,400,000916,0003,932,0003,377,0004,466,0001,861,000216,0005,574,0004,374,000
Net income
-17m
L-32.24%
753,00048,00074,000376,000-3,085,000-1,672,000-674,000578,0009,595,000-4,468,000-12,052,000-21,107,000-30,486,000-22,431,000-24,384,000-16,523,000
CFO
-10m
L-43.53%
956,0001,824,0002,646,0002,551,000-5,209,0002,206,0001,487,000487,0001,798,0000-10,392,000-15,112,000-28,308,000-20,110,000-18,178,000-10,266,000
Dividend
Mar 30, 20170.0239 SEK/sh

Profile

QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.
URL
https://www.quiapeg.com/
IPO date
Jun 21, 2005
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,374
-21.53%
5,574
2,480.56%
216
-88.39%
Cost of revenue
6,184
8,026
9,954
Unusual Expense (Income)
NOPBT
(1,810)
(2,452)
(9,738)
NOPBT Margin
Operating Taxes
4,295
2,431
Tax Rate
NOPAT
(1,810)
(6,747)
(12,169)
Net income
(16,523)
-32.24%
(24,384)
8.71%
(22,431)
-26.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,675
22,477
19,953
BB yield
Debt
Debt current
20,611
315
778
Long-term debt
15,207
17,021
Deferred revenue
Other long-term liabilities
(15,207)
1,000
Net debt
20,510
12,956
12,458
Cash flow
Cash from operating activities
(10,266)
(18,178)
(20,110)
CAPEX
(5,574)
(8,594)
Cash from investing activities
(24,374)
(5,574)
(8,594)
Cash from financing activities
32,175
20,977
25,456
FCF
728
(4,747)
(12,010)
Balance
Cash
101
2,566
5,341
Long term investments
Excess cash
2,287
5,330
Stockholders' equity
2,621
(20,112)
(29,407)
Invested Capital
35,862
37,852
47,000
ROIC
ROCE
EV
Common stock shares outstanding
74,499
3,586
1,268
Price
Market cap
EV
EBITDA
2,049
916
(8,177)
EV/EBITDA
Interest
1,013
4,295
2,431
Interest/NOPBT